GlassScriptPhysician profile
David C Earl
NPI 1306113246
$2,715.95
in general payments reported to CMS, 2019-2025
18 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $224 · 2021: $95.97 · 2022: $338 · 2023: $119 · 2024: $600 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792 · Consulting Fee: $150 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.87 |
| Consulting Fee | $150.00 |
| Education | $115.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $540.57 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $241.39 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $239.98 | 2022-2025 | Uzedy |
| Alkermes, INC. | $223.44 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $215.79 | 2021-2024 | |
| Harmony Biosciences LLC | $172.56 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $142.09 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $125.00 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $124.04 | 2020 | |
| Xeris Pharmaceuticals, INC. | $123.97 | 2022 | |
| Pfizer INC. | $122.49 | 2025 | |
| Inspire Medical Systems, INC. | $113.56 | 2025 | Inspire |
| Sage Therapeutics, LLC | $99.97 | 2020 | |
| Neurocrine Biosciences, INC. | $85.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.37 | 2024 | Cobenfy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30.79 | 2023-2024 | Sunosi |
| Lilly USA, LLC | $21.38 | 2025 | Zepbound |
| Itamar Medical INC | $16.61 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.